Pentostatin Injection Shortage
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Pentostatin Injection (NIPENT) is currently unavailable from its sole manufacturer due to manufacturing delays.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on August 27, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Pentostatin.
What's in Shortage
Pentostatin Injection (brand name: NIPENT), dosage form Injection, therapeutic category Oncology, is currently in shortage. The presentation affected is Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01). The shortage was first posted on 08/27/2026 and last updated on 08/27/2026.
Which Manufacturers Are Affected
- Hospira, Inc., a Pfizer Company: Unavailable. Next delivery: Q2 2027; Estimated recovery: Q3 2027. Shortage per manufacturer: manufacturing delays. Contact: 844-646-4398.
Why There's a Shortage
The shortage reason is listed as Other, specifically manufacturing delays per the manufacturer.
What Patients Should Do
Patients should talk to their pharmacist about current availability, ask about possible alternatives if appropriate, and contact the manufacturer directly for the latest information. Patients should consult their healthcare provider for personalized guidance. This article does not provide medical advice.
Source
FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,027 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to August 27, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.